U.S. FDA issues EIR with VAI classification for Torrent Pharmaceuticals’ Indrad facility
Torrent Pharmaceuticals Indrad manufacturing facility receives closure notice from U.S. FDA following inspection
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Torrent Pharmaceuticals
Torrent pharma enters into non – exclusive patent licensing agreement with Takeda Pharma
The company aims to commercialise its gastrointestinal drug in India Torrent Pharmaceuticals recently announced that it has…
Ethical Nutraceuticals: Need of the hour
India Pharma Inc needs to arm itself with an evidence-based approach, significant investments and meaningful collaborations to…
Torrent Pharma to acquire Curatio Healthcare
Acquisition strengthens Torrent Pharma’s presence in the dermatology segment
Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent to partner for clinical trial of Molnupiravir
As per the directive of the SEC of the CDSCO, Dr Reddy’s will conduct the clinical trial and the other four pharma companies will…
Lilly signs licensing agreements with Dr Reddy’s, MSN Labs and Torrent Pharma for Baricitinib
On May 10, Lilly had also announced the signing of three Voluntary License Agreements with Cipla, Lupin and Sun Pharma Industries
Torrent Pharma posts consolidated PAT of Rs 310 crore in Q2FY21
Torrent Pharmaceuticals has reported financial results for the period ended September 30, 2020.
Torrent Pharma stock loses 3 per cent on US FDA warning letter
Stock of the drug firm was down 2.61 per cent at Rs 1,622.60 on the BSE
Torrent Pharma gets warning letter from US FDA for Gujarat facility
The company is committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities…
Dr Reddy’s halts worldwide supply of ranitidine
USFDA probing into the reported impurity N-nitrosodimethylamine in it at low levels